Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, August 26, 2016 at 3:00pm CET (9:00am EDT) to discuss financial results for the first half of 2016, as well as to provide a second quarter business update.
To participate in the conference call, please select your phone number below and use the confirmation code 49998398. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.
A replay of the webcast will also be available at the argenx website.
About argenx
argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.
argenx is listed on the Euronext Brussels exchange under the symbol ARGX.
|
Dial-In Numbers: Participant Free Call Dial-In Numbers: |
|
UK |
0800 694 0257 |
|
Participant Standard International Dial-In: |
|
UK Standard International |
+44 (0) 1452 555 566 |
|
Participant UK Local Call Dial-In Numbers: |
|
UK |
0844 493 3800 |
|
UK National Call |
0871 700 0345 |
|
Participant Local Call Dial-In Numbers: |
|
Australia |
0290 371 687 |
|
Austria |
0192 865 68 |
|
Belgium |
0817 000 61 |
|
Croatia |
0177 766 11 |
|
Czech Republic |
2288 804 60 |
|
Denmark |
3272 7625 |
|
Finland |
0923 195 187 |
|
France |
0176 742 428 |
|
Germany |
0692 222 3479 |
|
Germany |
0692 222 4918 |
|
Hungary |
0618 088 303 |
|
India |
0223 098 5304 |
|
Ireland |
0143 196 48 |
|
Ireland |
0150 601 53 |
|
Italy |
0236 008 146 |
|
Latvia |
6778 2516 |
|
Luxembourg |
2088 0695 |
|
Netherlands |
0207 176 886 |
|
New Zealand |
0992 917 07 |
|
Norway |
2156 3013 |
|
Poland |
2230 701 18 |
|
Romania |
0318 144 957 |
|
Russia |
4996 771 036 |
|
Slovenia |
0160 093 64 |
|
South Africa |
2110 032 02 |
|
Spain |
9141 436 69 |
|
Sweden |
0850 336 434 |
|
Switzerland |
0565 800 007 |
|
USA |
1631 510 7498 |
For further information, please contact:
Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, estimates, anticipates, expects, intends, may, will, or should, and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’ actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
